A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Bibliographic Details
Main Authors: Yunxin Chen, Sathish Kumar Gopalakrishnan, Melissa Ooi, Rehena Sultana, Li Hui Lim, Nicholas Grigoropoulos, Shin Yeu Ong, Mingge Xu, SGHMM1 Investigators, Wee Joo Chng, Yeow Tee Goh, Chandramouli Nagarajan
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00544-x

Internet

https://doi.org/10.1038/s41408-021-00544-x

Similar Items